Doctors Drilon, Rotow, Stinchcombe, and Saxena participated in a roundtable discussion about therapies targeting certain biomarkers in patients with non-small cell lung cancer (NSCLC). The expert panel agrees that with the advent of approved and potentially promising treatments for specific mutations and fusions in NSCLC and other cancers, broad-platform testing early in disease is critical to offering patients the best chance at successful outcomes. Dr. Stinchcombe points out that new studies, one in particular, have demonstrated that circulating tumor DNA (ctDNA) can have similar effectiveness to standard routine tumor testing, but can yield results up to seven days faster, which is very important in getting patients started on treatment as early as possible.

Review the full panel discussion transcript by clicking here.